Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB0006648157 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60p -6.59% 8.50p 8.60p 8.62p 9.02p 8.42p 9.02p 9,439,916 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27.8 -20.3 -0.6 - 262.52

Oxford Biomedica Share Discussion Threads

Showing 98651 to 98673 of 98675 messages
Chat Pages: 3947  3946  3945  3944  3943  3942  3941  3940  3939  3938  3937  3936  Older
DateSubjectAuthorDiscuss
20/7/2017
15:36
Hmmm falling back. Where to now back to 8p?
guyswonga74
20/7/2017
09:34
I know.I have french phone language changing to me all the words
luxsuspick
20/7/2017
09:15
Luxus, OXO is a stock not a share
ph1ts
20/7/2017
09:13
HTTPS://seekingalpha.com/article/4088881-novartis-will-hit-100-year?auth_param=1d8lsm:1cmvt8c:129071792dfefebfdce2910dbefd33e8&uprof=82&dr=1#alt1 As we all know, this industry is all about getting quality-approved drugs to market first. Well, Novartis could be on the cusp of a transformational leap in its bid to become the first company to have an approved cell therapy for cancer patients. The FDA advisory committee recently recommended Novartis’ CTL019 in this area, which looks really encouraging. Remember there is a huge European market at Novartis’ disposal here also. We should know fairly soon if this or other indications get approved. Again it is all about targeting markets with unmet needs which Novartis seems to have done here again. CTL019 could become the first cancer treatment in cell therapy. This is a huge market with an unmet need. Novartis Will Hit $100 This Year
marcusl2
20/7/2017
09:11
Wonga, if you think that 8 to 9p is a lot more than most on here then you've likely grasped the wrong end of this particular stick.It's true that a lot averaged down at 2p, but many of those held already from much higher prices.
harry s truman
20/7/2017
08:47
Hmmm 2-1 buys out weigh sells and share is down. Bought in at 8.6p so a lot higer then most on here but can see 20p plus in a few months
guyswonga74
20/7/2017
05:45
Oxo share its bombastic.For me, the stock remains 10to 12p next days.i do not let me manipulate some people. Blude sayings like 7 p .... Hold and do not give out of hand
luxsuspick
19/7/2017
21:57
lentiviral transduced huCART-meso HTTPS://clinicaltrials.gov/ct2/show/NCT03054298
marcusl2
19/7/2017
21:49
Thanks for the Ezra Cohen, Marcus, good article. Interesting to see mention at the end of oncolytic viruses (I have some shares in Oncolytics Biotech). Yet another approach.
rrr
19/7/2017
21:40
Thanks Marcus, the ingenious scientists are already at it then. Novartis prominent. Do you have anything more on "A novel, fully human antimesothelin CAR (huCART-Meso) recently began clinical testing in solid tumors."? Hi phil, glad you agree surgery might have a role - along, no doubt, with the hi-tech that Marcus is telling us about. r
rrr
19/7/2017
21:38
Next days...a few punters,price drops to 7p...I wil jump in for more of them.Don't be scared of a drop some people are taking profit out
costax1654x
19/7/2017
21:29
HTTP://www.onclive.com/web-exclusives/cohen-discusses-immunotherapy-combos-car-tcell-therapy-in-hnscc?p=1
marcusl2
19/7/2017
21:24
Promising; Novartis and the University of Pennsylvania. A chimeric antigen receptor T-cell (CAR-T) therapy for glioblastoma (GBM) successfully crossed the blood–brain barrier to reach tumors in the brain, appeared safe, and reduced levels of its epidermal growth factor variant III (EGFRvIII) tumor target in GBM cells, in a first-in-man trial carried out by Novartis and the University of Pennsylvania The autologous EGFRvIII-directed CAR-T therapy has been developed through an ongoing collaboration "There is a dramatic expansion of inhibitory T cells in the tumors after the infusion, much more significant than what you see without the CAR T cells," notes trial leader, Donald M. O’Rourke, M.D., associate professor of neurosurgery at University of Pennsylvania’s Perelman School of Medicine. "This tells us that we need to begin to modulate the microenvironment to make it more favorable... . There may be a synergy between CAR T cells and inhibition of these pathways with small-molecule drugs or checkpoint blocking antibodies." Novartis and the University of Pennsylvania are working to develop multiple candidates. “As part of our ongoing research and development collaboration with the University of Pennsylvania, researchers are generating a pipeline targeting hematological malignancies as well as solid tumors with CAR-T therapies. CTL119 is a humanized anti-CD19 CAR in initial clinical development for multiple B-cell malignancies. CART-BCMA is a novel, fully human CAR targeting B-cell maturation antigen (BCMA) under evaluation in multiple myeloma. A novel, fully human antimesothelin CAR (huCART-Meso) recently began clinical testing in solid tumors.” HTTP://www.genengnews.com/gen-news-highlights/human-car-t-cell-glioblastoma-trial-generates-clues-for-improving-treatment/81254675
marcusl2
19/7/2017
20:45
solid tumours; The reason it has not seen much CAR-T application is because the tumor microenvironment (TME) is not conducive to T cells proliferation. The TME is immunosuppressive in at least three different ways - through Cancer-associated Fibroblasts (CAFS), Reactive Nitrogen Species and the Tumor Vasculature itself. CAFs restrict T cells to the stroma through means of a thick extracellular matrix (ECM). They also secrete CXCL12 which coats the T cells and blocks their tumor entry. As is obvious, both these mechanisms are therapeutic targets. Similarly, too, tumor vasculature induced T cell blocking mediated through VEGF is also a therapeutic target; Pfizer’s (PFE) Axitinib is a potent VEGF inhibitor. Celyad’s NKR-2 CAR-T complements all these various technologies as combination therapies where one part of the combo will improve T cell proliferation in the TME through one or more of these anti-immunosuppressors, while the other will attack cancer cells with great specificity. HTTPS://www.celyad.com/en/news/celyad-grants-to-novartis-a-non-exclusive-license-for-its-allogeneic-tcr-deficient-car-t-cells-patents HTTP://www.fiercebiotech.com/biotech/novartis-licenses-car-t-patents-from-bluebird-celyad
marcusl2
19/7/2017
20:44
rrr, That would seem logical, certainly a first step with 5t4
philh75
19/7/2017
20:29
I wonder if surgical removal of a primary tumour followed by CAR-T to (hopefully) clear anything the surgery has missed and micro-metastases may be an approach to solid tumours in appropriate cases?
rrr
19/7/2017
17:33
'Are they interested in CAR T 5T4 ?' One thing that has always made me wonder about 5T4 is.. if it really is an attractive target, why did Wyeth/Pfizer do such a pathetic job of developing their ADC. Perhaps because ADCs have never really taken off... Unlike other targets, 5T4 does not, I don't think, lend itself so much to inhibition/suppression/stimulation and the effector function of antibodies alone may not be potent enough ie. if Pfizer didn't progress the ADC rapidly, then that explains why no other Ab approaches. Which brings us back to 5T4 as an immunotherapy target. Well.... Sanofi did take on Trovax initially, so it would seem to be a sufficiently attractive target - more now just that Trovax as a mechanism isn't favoured. So, I'd conclude that if CAR-T takes off, which it clearly is doing at present, then CAR-5T4 could well be attractive in terms of its potential overall. BUT... what it rests on here for CAR-T, is more the wider role of CAR-T in solid tumours - and more specifically, those that exhibit sufficiently high levels of 5T4 IF CAR-T doesn't work sufficiently in solid tumours, then it will not be enough vs alternative drug approaches... and CAR-5T4 will not be sought after. ie. I'd say, watch for excitement in the solid tumour space with CAR-T in general. Clearly if there's enough hope, then OXB could see partner desire just on that - that is, if companies want to punt on a solid tumour CAR-T, then 5T4 could seem a good bet (above caveats aside) It may be that efficacy in solid tumours requires additional tweaks to the CAR-T and I'm not sure OXB will have applied those - so even if their current agent isn't right, it may pave the way for an alternative via someone with more of the IP.
stocktastic
19/7/2017
15:59
Yes it does Marcus. I know I keep saying it but this is such an amazing moment for people. It's the accumulated result of years of science and medicine and now you and I and our families and friends will see a real difference. Of course there has been incremental progress in cancer therapy (and, importantly, diagnosis) over the years - but I believe the landscape changes quite sharply from here on - of course it won't all happen at once but it's a really fundamental change. In a very, very small way indeed we as long-standing OXB shareholders are part of that. It is good for the share price of course, which is nice, but it's the other bit that gets me excited. Yes I think, in time, we'll have T-cells mopping up cancers of all sorts, and used earlier and earlier. Solid tumours are a challenge for reasons of accessibility but my guess is that so much is now understood (though not by me!) that they will yield to the scientists' ingenuity in due course. rrr
rrr
19/7/2017
15:39
rrr, it sounds good doesn`t it? “detected a strong change in tone and optimism around the CAR-T program.” “enthusiastic about the ability to price CAR-T at very attractive levels as well as to also potentially move into the [chronic lymphocytic leukemia] indication, multiple myeloma and solid tumors.” Are they interested in CAR T 5T4 ?
marcusl2
19/7/2017
14:27
My thanks too Marcus, Harry and the other regular posters, this is the best board I have come across by far.
rrr
19/7/2017
14:02
Earlier this year, England’s cost watchdogs NICE ran the numbers and found that CAR-T medications could be worth up to $649,000, assuming that patients gain 10 quality-adjusted life years over the current standard of care. At the time, a Novartis spokesperson said "it is too early for us to comment on pricing; however, we will at the time of approval." Asked to confirm the Narasimhan's remarks on pricing and payment, a Novartis spokesperson reiterated that it’s “too early for us to comment on pricing.” Stem cell transplants and follow-up treatment can cost upwards of $800,000. Narasimhan’s statements come just days after an investor and analyst meeting for Novartis, where the company’s management talked up CAR-T prospects. In their coverage of the meeting, Jefferies analysts wrote that they “detected a strong change in tone and optimism around the CAR-T program.” RELATED: CAR-T drugs worth up to $649K in childhood leukemia, says U.K. report In a note afterward, Jefferies analyst Jeffrey Holford wrote that Novartis management was “enthusiastic about the ability to price CAR-T at very attractive levels as well as to also potentially move into the [chronic lymphocytic leukemia] indication, multiple myeloma and solid tumors.” Those indications would be big expansions, potentially adding thousands more patients eligible for treatment. HTTP://www.fiercepharma.com/pharma/novartis-car-t-med-could-rank-among-world-s-costliest HTTP://www.biospace.com/news_story.aspx?StoryID=463375&full=1
marcusl2
19/7/2017
11:04
Agreed. Thanks Marcus.
moopdoom
19/7/2017
11:03
For those who like to buy and hold on the run up to pivotal news. Check MOS, news on figures out of India due to land anytime between now and next Tuesday. Herd not arrived yet but MM shenanigans point to them having zero stock and not willing to go short. Has multi bagged in a day three times in last few years off the back of the kind of news which is about to land.
phil1969
Chat Pages: 3947  3946  3945  3944  3943  3942  3941  3940  3939  3938  3937  3936  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170720 16:52:47